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Introduction: Single time-point unidimensional tumor thickness 
measurements define measurable disease for clinical trial inclu-
sion and also constitute a field in the International Association for 
the Study of Lung Cancer prospective mesothelioma staging data-
base. The modified Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines for mesothelioma did not alter the 10-mm min-
imum tumor measurement recommendation. However, as computed 
tomography technology has advanced, we sought to examine whether 
interobserver agreement was acceptable at smaller tumor thickness 
in mesothelioma.
Methods: The primary observer selected 170 discrete measure-
ment sites from 105 thoracic computed tomography scans from 50 
consenting patients with pleural mesothelioma. Sites represented a 
range of tumor thickness, lesion morphology, and location. The outer 
(parietal) tumor margin was marked at each site and presented to 
five additional observers, who then selected the visceral margin of 
the tumor to create a line segment that captured tumor thickness. 
Relative differences among the observer measurements were esti-
mated using a random-effects analysis of variance model to identify 
the smallest tumor thickness at which linear measurements could be 
made reliably.
Results: Systematic bias was observed, with some observers con-
sistently measuring larger or smaller thicknesses than the thickness 
measured by others. The mean range across all 170 sites was 15.1% 
of the mean per-site measurement (SD = 9.1%; median range, 
13.1%). Measurements acquired at sites with mean tumor thick-
ness less than 7.5 mm demonstrated interobserver variability with a 
75th percentile included 20% of the tumor thickness. The 95% con-
fidence interval for relative interobserver measurement differences 
obtained for mean measurement lengths in the range 5 to 7.5 mm 
does not exceed the RECIST thresholds.
Conclusions: This study has implications for the definition of mini-
mally measurable tumor adopted by clinical trial and staging pro-
tocols. Although the statistical findings suggest that a reduction in 
“minimally measurable disease” from 10 mm to 5 or 7.5 mm might 
be warranted, clinical factors may ultimately dictate the most appro-
priate definition.
Key Words: Malignant pleural mesothelioma, Response assessment, 
Staging, Thoracic computed tomography, Interobserver variability.
(J Thorac Oncol. 2014;9: 1187–1194)
Linear measurement of tumor diameter on computed tomog-raphy (CT) scans remains the standard clinical metric for 
the evaluation of tumor growth or response to therapy. The 
Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines1 specify a tumor measurement approach (a single 
unidimensional measurement of the tumor’s longest diam-
eter) and a set of thresholds to convert numeric change in 
tumor measurements across temporally sequential CT scans 
into categories of tumor response (complete response, partial 
response, stable disease, and progressive disease). The modi-
fied RECIST guidelines2 changed the tumor measurement 
approach, specifically for mesothelioma, from longest tumor 
diameter to tumor thickness perpendicular to the chest wall 
(or mediastinum) to accommodate the unique morphology of 
this disease.
Also contained within the RECIST guidelines is the 
specification of “measurable disease” as a tumor with a 
minimum diameter of 10 mm, which, for geometric and CT 
partial-volume–effect considerations, is a threshold that rep-
resents twice the then-state-of-the-art 5-mm thickness of CT 
section images. Modified RECIST did not change this thresh-
old, which has not been challenged in the intervening years, 
even as CT technology has evolved. RECIST was conceptu-
alized under assumptions of spherical tumor morphology. A 
10-mm-diameter (“just-measurable”) spherical tumor has a 
volume (i.e., tumor burden) of 523 mm3; however, one pos-
sible morphological representation of mesothelioma tumor 
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with a “just-measurable” 10-mm in-plane thickness on a sin-
gle 5-mm CT section encompasses a volume of 7672 mm3 (the 
equivalent of a 24.5-mm-diameter spherical tumor)3 (Fig. 1). 
Given that the anatomical extent of mesothelioma is rarely (if 
ever) constrained to a single CT section, the actual volume of 
a tumor with 10-mm in-plane thickness will likely be much 
greater than the equivalent of a 24.5-mm-diameter spherical 
tumor. Consequently, clinical trials that require “measurable 
disease” under RECIST as a criterion for enrollment may 
disadvantage subjects and the success of the trial through 
a greater baseline tumor burden. Following the rationale of 
RECIST that “measurable disease” should be defined as at 
least twice the thickness of CT section images, advances in 
CT technology may justify a revised definition, because state-
of-the-art scanners are capable of section thicknesses less than 
1 mm, and section thicknesses less than 3 mm have become 
more common.
Another factor that should be considered when defin-
ing “measurable disease,” however, is observer measurement 
variability, a concept alluded to in the RECIST guidelines.1,4 
Measurements, to be a reliable quantitative tumor assessment 
metric on which patient management decisions are made and 
clinical trial efficacy is evaluated, must demonstrate an accept-
able level of variability across the observers who acquire those 
measurements. The increase in measurement variability with 
decreased size of the object being measured is a well-known 
trend,5 which lends credibility to the notion that some mini-
mum tumor size should be defined below which inherent mea-
surement variability would limit the practical utility of the 
acquired measurements. Although variability in mesothelioma 
tumor thickness measurements has been reported previously,6 
the impact of physical tumor characteristics on measurement 
variability has not been investigated.
The purpose of this study was to determine the depen-
dence of mesothelioma tumor thickness measurement vari-
ability on tumor thickness, lesion morphology, and anatomical 
location, with the aim of informing a mesothelioma-specific 
definition of “measurable disease” and optimal measurement 
site selection.
MATERIALS AND METHODS
A retrospective database of 105 thoracic CT scans 
from 50 patients with mesothelioma was collected from Sir 
Charles Gairdner Hospital in Perth, Western Australia. Images 
were intentionally selected from heterogeneous time points 
throughout the disease course to obtain a range of tumor thick-
ness and location. Scans had been performed on a GE Medical 
Systems (Milwaukee, WI) Hi Speed (n = 72), GE LightSpeed 
(n = 16), or Philips (Highland Heights, OH) Brilliance 64 
(n = 17) CT scanner. Peak voltage was 120 kVp for all scans, 
pixel size ranged from 0.57 to 0.91 mm, and section thickness 
was 0.625 mm (n = 2), 1 mm (n = 1), 1.25 mm (n = 2), 2.5 mm 
(n = 1), 5 mm (n = 96), 7 mm (n = 2), or 10 mm (n = 1). All 
images had been reconstructed as 512 × 512-pixel images.
With approval from the local Human Research Ethics 
Committee, each scan was reviewed by a medical oncologist 
(AKN) (the “primary observer”), who used an in-house image 
visualization and manipulation software package (Abras, ver-
sion 1.6) to identify 170 sites of mesothelioma tumor that 
represented a range of thicknesses, lesion morphologies, and 
anatomical locations across all scans. Through Abras, the pri-
mary observer identified a specific outer tumor margin point 
along the chest wall or mediastinal structures at each measure-
ment site and created a line segment that spanned the tumor 
from the outer tumor margin point to an appropriate location 
along the inner tumor margin, in accordance with the modi-
fied RECIST tumor measurement approach.2 The primary 
observer then categorized local tumor morphology (concave 
rind, convex rind, convex mass, or fusiform mass) (Fig. 2) and 
anatomical location (chest wall, mediastinum, anterior angle, 
or posterior angle; upper, middle, or lower zone of the thorax 
in the craniocaudal direction according to uniformly speci-
fied boundaries; outer tumor margin point along bone or soft 
tissue; and laterality). It is important to note that these 170 
measurement sites were not selected to capture foci of clinical 
relevance but rather to represent a range of tumor thicknesses 
and morphologies, with anatomical location a secondary 
consideration.
An observer study was conducted in which Abras was 
used to present each of five other physicians with the spe-
cific CT section and the same preselected fixed location of 
the outer tumor margin point at each of the 170 primary-
observer–defined tumor measurement sites. Each observer 
independently used Abras to create at each measurement site 
a line segment that spanned the tumor from the annotated 
predefined outer margin point to an appropriate location 
along the inner tumor margin (Fig. 3); the length of each 
observer’s line segment became the tumor thickness mea-
surement for that observer. This process was exactly the 
same as for the primary observer, except that the outer tumor 
margin point identified and recorded by the primary observer 
became the common fixed starting point for the measure-
ments of the other observers; no data regarding lesion mor-
phology or anatomical location were captured from these 
other observers.
Interobserver measurement variability was calculated 
as a function of mean tumor thickness measurement, lesion 
morphology, and anatomical location to identify the smallest 
FIGURE 1.  A two-dimensional example demonstrates that a 
10-mm-diameter circle (representing a spherical tumor) has 
a much smaller area (volume) than a 10-mm-thick annulus 
(representing a rind of mesothelioma tumor).
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thickness at which linear measurements could be made reliably. 
Comparisons were made with the RECIST tumor response cri-
terion of 20% for progression. Relative differences among the 
tumor thickness measurements of observers were estimated 
using a random-effects analysis of variance model as previ-
ously described.6 The following model was fitted using PROC 
MIXED in the SAS software (SAS Institute Inc., Cary, NC): 
log (y
ijkm
) = α + a
i
 + b
j(i)
 + c
k(ij)
 + r
m
 + ε
ijkm
, where y
ijkm
 is the 
length of each constructed line segment, and random effects are 
a
i
 (the patient effect), b
j(i)
 (the CT scan effect), c
k(ij)
 (the mea-
surement site effect), r
m
 (the rater effect), and ε
ijkm
 (the residual 
error). To estimate the relative differences for each morphol-
ogy type, location, and size category, separate random-effects 
models were fitted within each relevant subgroup.
The process by which an observer obtains a measure-
ment involves the angle that a constructed line segment 
makes with respect to the predefined outer margin point and 
the length of that line segment.6 Two observers might con-
struct line segments that extend from the outer margin point 
in the same direction but with different interpretations of 
inner tumor margin location; alternatively, observers might 
interpret inner tumor margin similarly but construct line seg-
ments that extend in different directions. To capture this sec-
ond effect, the angular spread of the line segments created by 
observers to capture tumor thickness measurements at each 
site was recorded; this analysis was possible because all line 
segments at a given measurement site shared a common fixed 
starting point. Summary statistics for the angular distribution 
data were computed.
RESULTS
Patient demographic and disease characteristics are sum-
marized in Table 1. Table 2 presents the distribution of tumor 
measurement site morphology and location as recorded by the 
primary observer. Approximately half (42.9%) of the measure-
ment sites were categorized as concave rind in local morphol-
ogy; the remaining sites were more equally distributed across 
convex rind, convex mass, and fusiform mass morphologies. 
The majority (62.9%) of measurement sites were located along 
the chest wall. The middle craniocaudal zone of the thorax 
contained 77.1% of the measurement sites, and 63.5% of the 
sites were defined by outer tumor margin points placed along 
bone rather than soft tissue. The measurement sites were nearly 
equally divided between right and left hemithoraces. Again, 
the sites were not selected to capture foci of clinical relevance 
but rather to represent a range of tumor thicknesses and mor-
phologies, with anatomical location a secondary consideration; 
accordingly, these data do not suggest generalizable distribu-
tions of tumor morphology or location in patients with meso-
thelioma, and any statistically significant differences that may 
FIGURE 2.  Examples of selected 
tumor measurement sites (indicated 
with "+") with local morphologies 
characterized as (A) concave rind, (B) 
convex rind, (C) convex mass, and 
(D) fusiform mass.
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exist among these data would not be relevant. These data do, 
however, indicate a clear preference for the primary observer 
to select tumor measurement sites along the chest wall and 
anchored by bone, and they indicate a tendency for the primary 
observer to avoid the placement of tumor measurement sites 
near the lung apices and lung bases, as recommended by the 
modified RECIST guidelines for mesothelioma.
Figure 4 presents a histogram of the per-site mean tumor 
thickness measurements. The mean tumor thickness measure-
ment at each of the 170 measurement sites was computed 
as the arithmetic mean of each of the six observers’ tumor 
thickness measurements at that site. The average of the mean 
measurements across all 170 sites was 11.61 mm (range, 
2.60–54.35 mm) with an SD of 8.19 mm. The median mean 
measurement across all sites was 9.68 mm (i.e., half of the 
170 measurement sites were smaller than 9.68 mm), which 
reflects the study’s aim to investigate measurement vari-
ability as a function of tumor thickness given that the cur-
rent minimum measurable tumor thickness has been set at 
10 mm; specifically, 87 of the 170 measurement sites had a 
mean measurement less than 10.0 mm. Each of the six scat-
ter plots of Figure 5 displays, for each of the 170 measure-
ment sites, the relative difference between the measurement 
of one observer and the average across all other observers 
as a function of the mean measurement (of all six observers) 
at the site. Approximately 154 (90.6%) of the measurements 
from Observer 0 (the primary observer) are less than the per-
site average measurement across all other observers, whereas 
FIGURE 3.  Observers were independently shown the image 
with the outer tumor margin point marked (red circle) at 
each site for measurement. The six observers’ tumor thickness 
line segments are shown superimposed, with the primary 
observer measurement arrowed.
TABLE 1.   Patient Characteristics (n = 50)
Characteristics N (%)
Sex
  Male 45 (90%)
  Female 5 (10%)
Histology
  Epithelioid 35 (70%)
  Biphasic 5 (10%)
  Sarcomatoid 5 (10%)
  Not specified 5 (10%)
Laterality
  Right 26 (52%)
  Left 24 (48%)
TABLE 2.  Distribution of Measurement Site (n = 170) 
Location and Morphology
Characteristic Classification N (%)
Local tumor morphology Concave rind 73 (42.9%)
Convex rind 27 (15.9%)
Convex mass 40 (23.5%)
Fusiform mass 30 (17.6%)
Anatomical location Chest wall 104 (62.9%)
Mediastinum 44 (25.9%)
Anterior angle 3 (1.8%)
Posterior angle 16 (9.4%)
Craniocaudal zone Upper 26 (15.3%)
Middle 131 (77.1%)
Lower 13 (7.6%)
Outer tumor margin point Bone 108 (63.5%)
Soft tissue 62 (36.5%)
Laterality Right 89 (52.4%)
Left 81 (47.6%)
FIGURE 4.  Distribution of the mean tumor thickness mea-
surement across all six observers at each of the 170 measure-
ment sites.
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136 (80.0%) and 143 (84.1%) of the measurements from 
Observers 2 and 5, respectively, are greater than the per-site 
average measurement across all other observers.
Figure 6 presents a histogram of the range of tumor 
thickness measurements at each site as a percent of the mean 
length at that site (reflecting interobserver variability). The 
range of tumor thickness measurements at a site was defined 
as the difference between the largest and smallest of the six 
observers’ measurements divided by their average. The mean 
range across all 170 sites was 15.1% of the mean per-site 
measurement with an SD of 9.1%, and the median range as 
a percent of the mean per-site measurement across all sites 
was 13.1%.
Figure 7 presents the range distribution data from Figure 
6 separated by local lesion morphology. The median range of 
measurements acquired for the convex mass lesion morphol-
ogy was less than the 25th percentile range of the three other 
lesion morphologies although this finding could be explained 
by the fact that line segments associated with convex mass 
lesions were statistically significantly longer than those asso-
ciated with the other lesion morphologies (Mann–Whitney U 
test). No statistically significant differences among the dis-
tributions of mean measurements were observed across the 
lesion anatomical location categories (Kruskal–Wallis test). 
Figure 8 presents the relative differences in tumor measure-
ments (i.e., the data in Figure 5 aggregated across observ-
ers) as box-and-whiskers plots over mean tumor thickness 
categories. The interquartile range and whisker span initially 
decrease with increasing mean tumor thickness measurement 
and then become more consistent for measurements acquired 
at sites with mean tumor thickness measurement greater than 
7.5 mm.
On the basis of the random-effects analysis of variance 
model, the 95% confidence interval for interobserver tumor 
thickness measurement differences was (−16.8%, 20.1%) across 
all measurements. The 95% confidence intervals for relative 
interobserver differences within the different lesion morphology, 
lesion location, and mean measurement length categories are 
presented in Table 3. The 95% confidence intervals are relatively 
constant across lesion morphology and measurement site loca-
tion, except that the confidence interval is smaller for convex 
masses, which, as mentioned above, tend to have longer tumor 
FIGURE 5.  Each scatter plot displays, for each of the 170 measurement sites, the relative difference between the measurement 
of one observer and the average measurement across all other observers as a function of mean measurement at the site.
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thickness measurements. The 95% confidence interval for rela-
tive interobserver measurement differences obtained for mean 
measurement lengths in the range 5 to 7.5 mm was −14.6% to 
17.1%; because the RECIST tumor response thresholds (−30%, 
+20%) fall outside this interval, it is therefore likely that, in 
tumors of this size or larger, assessments of response or progres-
sion are real and not simply due to interobserver variability.
The mean angular spread among observers’ measure-
ment line segments was 10.4 ± 5.6 degrees (range, 3.4–37.0 
degrees) across all measurement sites. Angular spread did not 
demonstrate a linear relation with mean tumor thickness at 
a measurement site (r2 = 0.012). When the relation between 
angular spread and mean tumor thickness was considered by 
lesion morphology (concave rind, convex rind, convex mass, 
or fusiform mass), anatomical location (chest wall, mediasti-
num, or anterior/posterior angle), or outer tumor margin point 
(bone or soft tissue), the r2 values ranged from 0.00015 to 
0.21. Tumor thickness range as a percent of mean measure-
ment at a site exhibited an r2 value of 0.011 when correlated 
with angular spread at the site.
DISCUSSION
Single time-point unidimensional tumor thickness mea-
surements define measurable disease for clinical trial inclusion. 
The modified RECIST guidelines did not alter the recommen-
dation of 10 mm for a minimally measurable lesion, but these 
guidelines also did not validate the use of this specific tumor 
thickness threshold in mesothelioma. Given that the notion of 
“minimally measurable lesion” derives, in part, from consider-
ations of observer variability and the correspondingly greater 
precision of measurements that accompanies reduced vari-
ability, the present study quantified observer variability in the 
acquisition of modified RECIST–based linear measurements 
of mesothelioma tumor thickness in an effort to empirically 
determine a definition of measurable lesion unique to meso-
thelioma. The statistical findings of this study suggest that a 
reduction in minimally measurable lesion thickness from the 
10 mm stipulated by RECIST for all tumors to a mesotheli-
oma-specific value of 5 or 7.5 mm might be warranted.
The RECIST tumor response thresholds were not 
derived from interobserver variability considerations and 
were not intended to define acceptable limits of such variabil-
ity (although the 20% threshold between “stable disease” and 
“progressive disease” was defined with an element of interob-
server variability in mind). The RECIST thresholds, however, 
provide a practical, clinical context in which interobserver 
variability may be evaluated. If variability among observers 
who use a particular measurement technique to independently 
FIGURE 6.  Distribution of the range of tumor thickness 
measurements across all six observers at each of the 170 sites 
as a percent of the mean measurement at that site.
FIGURE 7.  Distributions of the range of observ-
ers’ measurements at each site as a percent of 
the mean measurement at that site (interobserver 
variability) categorized by local lesion morphol-
ogy at the site.
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measure the same lesion on the same CT scan at the same time 
point is so large that the measurements acquired by these dif-
ferent observers, when compared, are likely to extend beyond 
the range of measurement differences categorized as “stable 
disease,” then that measurement technique would clearly lack 
clinical utility.
The findings of this study are directed at single time-
point measurements on what would be considered a baseline 
CT scan, that is, the setting in which the concept of “minimally 
measurable lesion” applies. Once a lesion measurement site is 
established on the baseline scan, that site is meant to be mea-
sured on all subsequent scans. Furthermore, previous results 
demonstrate that interobserver variability in the acquisition of 
mesothelioma measurements on follow-up scans is lower than 
for baseline scan measurements, because observers acquiring 
measurements on a follow-up scan, in practice, will visualize 
the baseline scan measurements7; the bias introduced by this 
visual reference necessarily reduces expected interobserver 
variability in the follow-up scan setting.
The underlying notion of modified RECIST is that lin-
ear measurements can be used as a surrogate for tumor bur-
den; the validity of this approach was not challenged by the 
present study. Although the use of area-based measurements 
for mesothelioma response assessment has been shown to suf-
fer from exaggerated levels of observer variability,7 the inves-
tigation of volumetric measurements has gained increased 
attention with promising results.8–11 The practical utility of 
volumetric measurements, however, remains an open topic of 
investigation. Linear measurements for response assessment 
remain simple, inexpensive, and widely used.
The consistent bias to longer or shorter measurements by 
some observers reinforces the recommendation that measure-
ments should be performed by the same observer at all time 
points during a clinical trial. However, although interobserver 
variability may be ameliorated by using the same observer for 
sequential measurements, the question of a minimum repro-
ducibly measurable tumor in mesothelioma may assume addi-
tional importance in a revision of mesothelioma staging. The 
International Association for the Study of Lung Cancer is cur-
rently collecting prospective data to inform potential revision 
of the staging of pleural mesothelioma. Exploratory informa-
tion that is currently being collected includes the maximum 
tumor thickness at three craniocaudal sites on the axial CT 
scan. It will be critical to understand the reproducibility of 
FIGURE 8.  Distributions of the 
difference between the measure-
ment of one observer and the aver-
age measurement across all other 
observers at each site as a percent of 
the mean measurement at that site 
aggregated across observers and sites 
and plotted as a function of mean 
site measurement.
TABLE 3.  The 95% Confidence Intervals for Relative 
Interobserver Differences for Lesion Measurements by Lesion 
Morphology, Lesion Location, and Mean Measurement 
Length
Characteristic Classification 95% CI (%)
Local tumor morphology Concave rind (−17.7, 21.6)
Convex rind (−19.2, 23.7)
Convex mass (−10.6, 11.9)
Fusiform mass (−18.2, 22.2)
Anatomical location Chest wall (−15.3, 18.1)
Mediastinum (−19.4, 24.1)
Anterior/posterior angle (−17.5, 21.2)
Mean measurement length <5 mm (−25.6, 34.5)
5–7.5 mm (−14.6, 17.1)
7.5–10 mm (−11.5, 13.1)
10–12.5 mm (−9.8, 10.8)
12.5–15 mm (−7.4, 8.0)
15–17.5 mm (−8.3, 9.1)
17.5–20 mm (−6.4, 6.9)
>20 mm (−6.8, 7.3)
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tumor thickness measurements among observers before any 
categorization and analysis for staging purposes.
Importantly, this study removed many sources of vari-
ability by preselecting and electronically presenting the parietal 
anchor for the measurement site to the observer. Even under 
these controlled conditions and with the ability to magnify the 
measurement window, interobserver variability remained high 
at smaller tumor thicknesses. This finding further validates the 
practical need for some defined tumor thickness threshold.
This study has important implications for the definition 
of “minimally measurable lesion” adopted by mesothelioma 
clinical trials. The findings suggest that a reduction in mini-
mally measurable lesion thickness from 10 mm to 5 or 7.5 mm 
might be warranted; however, real-world sources of variability 
that were not present in this study, including differences in 
patient positioning, differences in imaging technical param-
eters, and the acquisition of measurements by different read-
ers across the temporal sequence of patient scans, may impose 
a larger margin to this minimum. Ultimately, clinical factors 
may dictate the most appropriate definition of “minimally 
measurable lesion” in the mesothelioma setting.
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